Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy

Document Type : Research Articles

Authors

1 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University,Bangkok,Thailand

2 Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Chulalongkorn University, Bangkok, Thailand

3 Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok

Abstract

 
For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy treatment. The excision repair cross-complementing group 1 (ERCC1) plays an important role in DNA repair and has been related to resistance to platinum chemotherapy. This study aimed to investigate the effects of the ERCC1 (C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-based chemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH). DNA was extracted from peripheral blood lymphocytes and the single nucleotide polymorphism of ERCC1 was genotyped using a real-time PCR method with the TaqMan assay. The distribution of C/C, C/T and T/T genotypes was 57.7 %, 34.6 % and 7.7 %, respectively. The response rate to platinum-based chemotherapy in the wild type (C/C) of ERCC1 (C118T) was better than with the variant types (C/T and T/T) but the difference was not statistically significant (29.7% vs 9.1%, P=0.274). The results showed that a genetic polymorphism in ERCC1 might influence patient response to platinum-based chemotherapy. Further multicenter studies are now required to confirm the results of our study.

Keywords

Asian Pacific Journal of Cancer Prevention
Volume 17, Issue 11
November 2016
Pages 4917-4920

Files

History

  • Receive Date: 06 September 2016
  • Revise Date: 28 December 2016
  • Accept Date: 28 December 2016

Share

How to cite

Statistics